PCRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
192.4M
+8.5%
177.4M
-9.9%
196.9M
+9.7%
179.5M
-0.9%
181.1M
Cost of Revenue
44.2M
+21.3%
36.4M
-9.6%
40.3M
+17.6%
34.3M
-16.1%
40.9M
Gross Profit
148.2M
+5.2%
141.0M
-10.0%
156.6M
+7.8%
145.2M
+3.6%
140.2M
Operating Expenses
144.0M
+7.4%
134.1M
-13.1%
154.2M
+11.1%
138.9M
+5.4%
131.7M
R&D
30.2M
+7.7%
28.1M
-25.0%
37.5M
+44.2%
26.0M
-7.9%
28.2M
SG&A
91.8M
-2.3%
93.9M
-7.5%
101.6M
+10.7%
91.8M
+3.6%
88.6M
Operating Income
4.3M
-38.2%
6.9M
+195.0%
2.3M
-63.2%
6.4M
-25.1%
8.5M
EBITDA
26.2M
-7.1%
28.2M
+19.2%
23.7M
-14.0%
27.6M
-23.5%
36.0M
Net Income
4.7M
+59.6%
2.9M
+78.1%
1.6M
-69.9%
5.4M
+212.1%
-4847000
EPS (Basic)
$0.12
+71.4%
$0.07
+75.0%
$0.04
-66.7%
$0.12
+209.1%
$-0.11
EPS (Diluted)
$0.12
+71.4%
$0.07
+75.0%
$0.04
-66.7%
$0.12
+209.1%
$-0.11
Shares (Diluted)
40.3M
-1.5%
40.9M
-6.4%
43.7M
-1.7%
44.5M
-2.2%
45.5M
Pacira BioSciences (PCRX) โ€” Financials